Well it is not possible to know what the FDA looked at and how they arrived at their position ... I can only imagine they looked at each DP and categorised them by the amount of TNF1 ... there may have only been a small variance between the subgroups, but they may have tried to see if a higher concentrated TNF1 DP resulted in a better clinical outcome.
I think the only way to know is to possibly give a large cohort a dose from a DP with significantly lower concentration of TFN1.. and the other cohort gets a high concentration DP.
Mesoblast were able to demonstrate it in vitro, but the trial wasn’t set up to demonstrate this in vivo
FDA ODAC Meeting Material discussion analysis, page-375
-
- There are more pages in this discussion • 117 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |